Cariprazine and Netupitant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Netupitant
No brand names on recordCariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines can interact. Netupitant (used to prevent nausea from chemotherapy) slows down a liver enzyme called CYP3A4. That enzyme is what your body uses to break down cariprazine (Vraylar). When netupitant slows it, more cariprazine and its active form build up in your body. That means the effects and side effects of Vraylar (like drowsiness, restlessness, dizziness, or muscle stiffness) may become stronger.
The good news: this is very manageable. Your care team can simply lower your Vraylar dose while you are taking netupitant and watch how you feel. Please keep taking both as prescribed and check with your pharmacist or doctor before changing anything.
Mechanism: Netupitant is a moderate CYP3A4 inhibitor; cariprazine is a CYP3A4 substrate. Inhibition reduces clearance, increasing exposure (AUC/Cmax) of cariprazine and its long-acting active metabolite didesmethylcariprazine (DDCAR).
Direction: increased cariprazine/DDCAR effect and adverse-effect risk (EPS, akathisia, sedation). Evidence: probable. Severity: major.
Management (per labeling for a moderate CYP3A4 inhibitor):
- Schizophrenia/bipolar mania initiation: 1.5 mg PO every other day, titrate per response/tolerability.
- Bipolar depression/adjunctive MDD: 1.5 mg PO every other day.
- On stable 1.5 or 3 mg daily: reduce to 1.5 mg every other day.
- On 4.5 or 6 mg daily: reduce to 1.5 mg once daily.
- On inhibitor discontinuation: cariprazine dose may need to be increased per response.
What happens
Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure
Interaction Deep Dive
Giving cariprazine (which is metabolized by CYP3A4) together with a moderate CYP3A4 inhibitor can raise the levels of both cariprazine and its active metabolite, didesmethylcariprazine. For patients starting cariprazine for schizophrenia or bipolar mania who are already on a moderate CYP3A4 inhibitor, begin with 1.5 mg orally every other day, then increase to 1.5 mg orally every other day if warranted, guided by clinical response and tolerability. For those on a moderate CYP3A4 inhibitor being treated for bipolar depression or receiving adjunctive therapy for MDD, the dose is 1.5 mg orally every other day. If a moderate CYP3A4 inhibitor is started in a patient already stabilized on cariprazine, dosing should be modified as follows: for patients currently taking 1.5 or 3 mg once daily, reduce cariprazine to 1.5 mg orally every other day upon starting the inhibitor; for patients currently taking cariprazine 4.5 or 6 mg once daily, reduce to 1.5 mg orally once daily when the inhibitor is added. Should the moderate CYP3A4 inhibitor be stopped, the cariprazine dose may require an increase according to clinical response and tolerability1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
This is manageable with dose adjustment and monitoring by your care team. Because netupitant can raise cariprazine levels, your prescriber will typically tailor your cariprazine (Vraylar) dose while you are on netupitant.
- If you are starting cariprazine while on netupitant, a lower, less frequent starting dose is used and adjusted to how you respond.
- If you are already on a stable cariprazine dose, your team may reduce it (for example, dosing less often or at a lower amount).
- When netupitant is stopped, your cariprazine dose may be increased again.
What to do: Keep taking both as prescribed and do not change doses on your own. Tell your pharmacist or doctor you take both, and report any new drowsiness, restlessness, dizziness, or muscle stiffness.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In drug interaction studies, giving cariprazine 1.5 mg/day together with erythromycin (a moderate CYP3A4 inhibitor) 500 mg twice daily for 21 days led to an increase in cariprazine AUC (0 to 24 hours) and Cmax by roughly 50% 1. In one study that enrolled only White males receiving cariprazine 1.5 mg/day and erythromycin 500 mg twice daily (n=40), AUCs rose by 38% (cariprazine), 11% (desmethylcariprazine, an active metabolite), and 60% (didesmethylcariprazine, an active metabolite), while Cmax rose by 34%, 16%, and 62%, respectively. Tmax was not altered by coadministration with erythromycin 2.
Common questions
Can I take Cariprazine and Netupitant together?
Netupitant can raise cariprazine (Vraylar) levels and side effects by slowing its breakdown, so your care team will likely lower the cariprazine dose while you take netupitant and adjust it back when netupitant stops. Keep taking both as prescribed and check with your pharmacist or doctor before changing anything. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Netupitant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Netupitant interaction managed?
This is manageable with dose adjustment and monitoring by your care team. Because netupitant can raise cariprazine levels, your prescriber will typically tailor your cariprazine (Vraylar) dose while you are on netupitant. If you are starting cariprazine while on netupitant, a lower, less frequent starting dose is used and adjusted to how you respond. If you are already on a stable cariprazine dose… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Cariprazine or Netupitant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
- Szabo M, Hujber Z, Harsanyi J, et al: Coadministration of cariprazine with a moderate CYP3A4 inhibitor in patients with schizophrenia: implications for dose adjustment and safety monitoring. Clin Pharmacokinet 2024; 63(10):1501-1510. PubMed
Keep reading about Netupitant
Keep reading about Cariprazine
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist